

## **FLX193: A Potent, Selective CCR4 Antagonist for Allergic Disorders**

Lisa Moore, Betty Abraham, Delia Bradford, Dirk Brockstedt, Martin Brovarney, David Chian, Christophe Colas, Gene Cutler, Jeff Jackson, Scott Jacobson, Aparna Jorapur, Emily Karbarz, Paul Kassner, John Ketcham, Nathan Kozan, Lisa Marshall, Sachie Marubayashi, Andrew Ng, Abood Okal, Deepa Pookot, Omar Robles, Jerick Sanchez, Silpa Suthram, Oezcan Talay, Parch Tivitmahaisoon, Angela Wadsworth, David Wustrow, Ash Younai, Mike Zibinsky, Jacob Schwarz

FLX193 is a best-in-class, highly-potent and selective small molecule CCR4 antagonist for the treatment of allergic disorders. Th2 cells have been shown to play a key role in many allergic diseases including atopic dermatitis and asthma. FLX193 prevents the binding of CCL17 and CCL22 to CCR4 on Th2 cells and consequently their recruitment by the CCL17/CCL22 – CCR4 axis into the inflamed tissues. We have demonstrated that FLX193 effectively blocks the migration of mouse and human Th2 cells towards CCL17 and CCL22 in an in vitro chemotaxis assay. Furthermore, in an Ovalbumin-induced airway inflammation model treating mice with FLX193 significantly decreased the cellular infiltrate and Th2 effector cytokines such as IL-5 and IL-13 in the bronchoalveolar lavage fluid (BALF). Blocking CCR4 also significantly reduced ear swelling in a Th2-dependent oxazolone-induced delayed-type hypersensitivity mouse model. FLX193 is expected to enter clinical development in 2019.